The I-Hart study, which enrolled 40 people with Type I diabetes, found that Dexcom’s device reduced patients’ time spent in hypoglycemia by 43 minutes.
DexCom (NSDQ:DXCM) touted data today from a head-to-head trial comparing its G5 mobile continuous glucose monitoring system with Abbott (NYSE:ABT) recently-approved FreeStyle Libre Flash glucose monitoring system.
The I-Hart study, which enrolled 40 people with Type I diabetes, found that Dexcom’s device reduced patients’ time spent in hypoglycemia by 43 minutes, while Abbott’s system increased patients’ time spent in hypoglycemia by 19 minutes.
The trial also showed that the G5 system cut time spent in hypoglycemia at night by 24 minutes, while use of the Libre system increased time spent in hypoglycemia at night by 9 minutes.
